Summary financial statements

Summary consolidated income statement			2007		2006
	Business performance £m	Restructuring costs £m	Total £m	Growth CER%	£m
Turnover
Pharmaceutical	19,233	-	19,233	-	20,078
Consumer Healthcare	3,483	-	3,483	14	3,147
Total turnover	22,716	-	22,716	2	23,225
Cost of sales	(5,206)	(111)	(5,317)	8	(5,010)
Gross profit	17,510	(111)	17,399	-	18,215
Selling, general and administration	(6,817)	(137)	(6,954)	-	(7,257)
Research and development	(3,237)	(90)	(3,327)	(1)	(3,457)
Other operating income	475	-	475		307
Operating profit	7,931	(338)	7,593	3	7,808
Finance income	262	-	262		287
Finance costs	(453)	-	(453)		(352)
Share of after tax profits of associates and joint ventures	50	-	50		56
Profit before taxation	7,790	(338)	7,452	2	7,799
Taxation	(2,219)	77	(2,142)		(2,301)
Profit after taxation for the year	5,571	(261)	5,310	3	5,498
Profit attributable to minority interests	96	-	96		109
Profit attributable to shareholders	5,475	(261)	5,214		5,389
	5,571	(261)	5,310		5,498
Basic earnings per share (pence)			94.4p	5	95.5p
Diluted earnings per share (pence)			93.7p		94.5p


Summary consolidated balance sheet	2007 £m	2006 £m
Total non-current assets	17,377	14,561
Total current assets	13,626	10,992
Total assets	31,003	25,553
Total current liabilities	(10,345)	(7,265)
Total non-current liabilities	(10,748)	(8,640)
Total liabilities	(21,093)	(15,905)
Net assets	9,910	9,648
Shareholders'equity	9,603	9,386
Minority interests	307	262
Total equity	9,910	9,648


Summary consolidated cash flow statement	2007 £m	2006 £m
Net cash inflow from operating activities	6,161	4,357
Net cash outflow from investing activities	(3,009)	(1,521)
Net cash outflow from financing activities	(1,741)	(4,792)
Increase/(decrease) in cash in the year	1,411	(1,956)
Exchange adjustments	48	(254)
Cash and bank overdrafts at beginning of year	1,762	3,972
Cash and bank overdrafts at end of year	3,221	1,762
Cash and bank overdrafts at end of year comprise:
Cash and cash equivalents	3,379	2,005
Overdrafts	(158)	(243)
	3,221	1,762